ADBE
50
3
HCA
37
7
CME
59
3
GIS
47
13
PCG
59
9
INTU
54
2
BIIB
36
8
DIS
70
2
FMC
23
7
PNR
56
2
APH
53
3
IPG
43
3
AIG
38
5
KO
44
2
ABT
54
4
NKE
36
2
TMO
52
8
CNX
67
4
KIM
58
2
ADT
12
2
ADBE
50
3
HCA
37
7
CME
59
3
GIS
47
13
PCG
59
9
INTU
54
2
BIIB
36
8
DIS
70
2
FMC
23
7
PNR
56
2
APH
53
3
IPG
43
3
AIG
38
5
KO
44
2
ABT
54
4
NKE
36
2
TMO
52
8
CNX
67
4
KIM
58
2
ADT
12
2
Financhill
Back

ImmunoPrecise Antibodies 10K Form

Sell
31

IPA
ImmunoPrecise Antibodies

Last Price:
$0.40
Seasonality Move:
-4.76%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive IPA News And Ratings

See the #1 stock for the next 7 days that we like better than IPA

IPA Financial Statistics

Sales & Book Value

Annual Sales: $18.2M
Cash Flow: $-1.7M
Price / Cash Flow: 0
Annual Sales: $0.78
Price / Book: 0.53

Profitability

EPS (TTM): -0.77260
Net Income (TTM): $-20.3M
Gross Margin: $8.9M
Return on Equity: -68.99%
Return on Assets: -41.65%

ImmunoPrecise Antibodies Earnings Forecast

Key ImmunoPrecise Antibodies Financial Ratios

  • The Gross Profit Margin over the past 17 years for IPA is 49.16%.
  • The Selling, General & Administrative Expenses for IPA have been equal to 78.04% of Gross Profit Margin.
  • The Research & Development expenses have been 16.49% of Revenue.
  • The Interest Expense is -0.07% of Operating Income.
  • The Net Earning history of IPA is -110.85% of Total Revenues.
  • Per Share Earnings over the last 29 years have been positive in 16 years.

ImmunoPrecise Antibodies Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Life Sciences Tools & Services
Sector: Health Care
Current Symbol: IPA
Website: ipatherapeutics.com

Debt

Debt-to-Equity Ratio: 0.09
Current Ratio: 1.01
Quick Ratio: 0.71

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

IPA Technical Analysis vs Fundamental Analysis

Sell
31
ImmunoPrecise Antibodies (IPA) is a Sell

Is ImmunoPrecise Antibodies a Buy or a Sell?